In a recent randomized phase III clinical trial in metastatic colorectal cancer patients, the addition of the anti-epidermal growth factor receptor (EGFR) monoclonal antibody (MAb) cetuximab to bevacizumab and chemotherapy resulted in decreased progression-free survival, in particular for patients with the high-affinity FcgRIIIA.
These molecular interactions might explain the negative effect of the addition of cetuximab to bevacizumab and chemotherapy in the CAIRO2 trial.
materialS and metHodS immunohistochemical stainings
Formalin fixed and paraffin embedded tumors from ten untreated stage III colorectal cancer patients, of whom the majority was moderately differentiated, 1 well and 2 were poorly differentiated, were selected from the pathology archive of the Leiden University Medical Center. All patients showed recurrent disease at follow-up. Staining for NK cells and M2 macrophages was described before (12) .
cell-cultures
Colorectal adenocarcinoma cell lines LoVo and HCT-15 were kindly provided by Dr. van Wezel (Leiden University Medical Center, the Netherlands) and epidermoid skin cancer line A431 was obtained from ATCC (Manassas, VA, USA). M2-type macrophages and dendritic cells (DCs) were differentiated from purified CD14 + monocytes (MACS, Miltenyi Biotec, Bergisch Gladbach, Germany) and differentiated as previously described (12) , using M-CSF (R&D, Minneapolis, USA) or GM-CSF (Invitrogen) with IL-4 (Invitrogen). Cells were activated by 250 ng/ml LPS (Sigma-Aldrich, St. Louis, USA) or tumor cells with MAbs cetuximab (Erbitux®, Merck, Darmstadt, Germany), rituximab or bevacizumab (Mabthera® and Avastin®, respectively; Roche, Welwyn Garden City, UK).
experimental conditions
At day 6 of the monocyte differentiation cultures, tumor cell lines were plated in a density of 50.000 cells per well in 48-wells plates. After 2 h, 250 ng/ml LPS or MAbs were added together with M2 macrophages in a density of 100.000 cells per well. After 24 h, supernatants were collected and analyzed for IL-10 (Sanquin, Amsterdam, Netherlands), IL-8, VEGF (eBioscience, Vienna, Austria) and IL-12p70 (BD-Biosciences, Minneapolis, MN, USA) production. Macrophages were removed from the culture plates by scraping and stained with monoclonal antibodies (all purchased from BD-Biosciences, except for anti-PD1-L from eBioscience). Samples were recorded using a FACS Calibur with Cellquest software (BD-Biosciences). Data were analyzed with FlowJo software (Tree star, Ashland, USA). Macrophages were separated from tumor celllines by gating for HLA-DR.
Genotyping
Genomic DNA was isolated from monocytes with MagnaPure Compact (Roche, Almere, Netherlands) and genotyping for FCGR3A c.818A>C (C_25815666_10; rs396991) was performed as previously described (7) . Activation of M2 macrophages by cetuximab 7 reSultS colon carcinomas are heavily infiltrated with type 2 macrophages, but not with nk cells.
To investigate immune cell infiltration of colorectal cancers, we stained ten tumors for the common macrophage marker CD68, and the scavenger receptor CD163, which is typically expressed by M2-type macrophages. All colorectal tumors were extensively infiltrated with this type of macrophages (figure 1a). By contrast, hardly any NK cells were observed using the NKlineage specific receptor NKp46. We thus envisage that cetuximab treatment might impact on these infiltrating macrophages, and that local ADCC via NK cells plays a minor role.
The influence of cetuximab on macrophages was studied on freshly isolated monocytes that were differentiated in vitro into CD1a -CD14 + CD163 + macrophages (12) . The expression of Fcg receptors FcgRI (CD64), FcgRII (CD32) and FcgRIIIA (CD16) and release of cytokines after activation by the strong TLR stimulus LPS was examined (figure 1b, c). M2 macrophages strongly displayed all three Fc-binding receptors and produced high amounts of the anti-inflammatory IL-10, as well as IL-8 and the pro-angiogenic VEGF, but not the immunostimulatory IL-12. Control monocyte-derived DCs displayed an opposite profile, which is in line with their T-cell stimulating function. These data strongly suggested that M2-type macrophages could potentially be stimulated by MAbs to exert an anti-inflammatory and pro-angiogenic role in the tumor microenvironment.
cetuximab induces activation of type 2 macrophages
M2 macrophages were then activated by cetuximab in the presence of tumor cells. Three tumor lines were used (A431, LoVo and HCT-15) and flow cytometry analysis showed that A431 highly expressed EGFR, whereas EGFR staining of LoVo and HCT-15 was much lower (figure 2a). Importantly, co-culture of macrophages with cetuximab-opsonized A431 tumor cells resulted in production of IL-10 and IL-8, whereas EGFR-low tumors LoVo and HCT-15 did not activate macrophages (figure 2b, suppl figure 1). Notably, the release of IL-8 upon cetuximab treatment exceeded that of the positive control LPS (suppl figure 1) . The A431 tumor cells spontaneously produced VEGF, so this mediator could not be used in succeeding experiments to determine macrophage activation. To corroborate the notion that macrophage activation was the result of cross-linking Fcg receptors, we incubated tumor cells with MAbs specific for the non-expressed CD20 (rituximab), or the soluble VEGF (bevacizumab), both containing the same IgG 1 isotype. This did not lead to IL-10 production (figure 2c), suggesting that only membrane-bound proteins as EGFR can efficiently trigger macrophages via FcgR. Furthermore, competition of Fc-binding by high concentrations of rituximab resulted in a dose-dependent decrease of IL-10 production (suppl figure 2) . Interestingly, IL-10 was also not detected when cetuximab was coated on culture plates (figure 2c), suggesting that the molecular interaction of EGFR-cetuximab-FcgR required the flexibility of fluid membranes for proper cross-linking.
The cetuximab mediated activation of M2 macrophages was dose-dependent ( figure 3 ) and concentrations as low as 10 ng/ml were sufficient to down-regulate cell surface levels of CD16 and to up-regulate the inhibitory molecule PD1-L (figure 3a) and to release IL-10 and IL-8 (figure 3b, suppl figure 1). These data showed that very low concentrations cetuximab induced the release of anti-inflammatory mediators from M2 macrophages through cross-linking of Fcg receptors.
effect of fcGriiia polymorphism
Addition of cetuximab to bevacizumab and chemotherapy in the CAIRO2 trial decreased the progression-free survival of metastatic colorectal cancer patients, especially for those with high affinity FcgRIIIA genotype encoding the valine residue (6, 7) . We examined the influence of this polymorphism on the degree of M2 macrophage activation by cetuximab using 22 healthy donors, consisting of 12 homozygous 158-Phe and ten 158-Val carriers ( figure 4 ). Analysis of IL-10 release and CD16 down-regulation on M2 macrophages showed an apparent stronger activation of cells with the high affinity valine allele ( figure 4 ). These differences did not reach statistical significance for cytokine release, most likely due to high variation within the groups and very high production (figure 4a and suppl figure 1, respectively). Notably, macrophage activation in this system is presumably also mediated by other Fcg receptors, such as FcgRI, resulting in less pronounced differences between 158-Phe and 158-Val carriers. In conclusion, our data show that cetuximab can induce the release of anti-inflammatory mediators from M2 macrophages and that this effect might explain the negative clinical effect of this MAb in the recent CAIRO2 study.
diScuSSion
Our data show that type 2 macrophages are abundantly present in colon carcinoma and are activated by cetuximab-opsonized tumor cells, resulting in anti-inflammatory and tumor promoting mediators, including IL-10 and VEGF. M2 macrophages are known to actively contribute to tumor growth via angiogenesis and immune suppression (10) . Previous research on the immune mechanisms of therapeutic MAbs has focused on anti-tumor effects such as ADCC or phagocytosis. ADCC mediated by NK cells or PBMCs has been described for cetuximab (5, 13) , however, staining for NK cells in colorectal carcinoma revealed that these cells are rare in colorectal cancers. Fcg receptors are also expressed by macrophages and these cells were abundantly present in this tumor type ( figure 1) . Previous studies have shown that macrophages are present in all stages of colon tumors and that higher numbers of macrophages are found in more advanced stages of disease (8, 9) . M2 macrophages are efficient in phagocytosis of rituximab-opsonized B cells (14) , but we question the relevance of this FcgR-mediated process for solid tumors like colorectal carcinoma. Based on our findings, we rather suggest that activation of intratumoral M2 macrophages leads to release of tumor-promoting mediators.
The detrimental effect of cetuximab addition in the CAIRO2 trial was unanticipated (6), since the combination of cetuximab and anti-VEGF therapy appeared effective in mouse models (15) (16) (17) However, the Fcg receptor-mediated effects by cetuximab could not be evaluated in these models, as the human Fc-region of cetuximab does not interact with the murine FcgRs. Future studies in mice expressing human FcgR might elucidate immune mechanisms of therapeutic MAbs and, importantly, better predict the outcome of combination studies. Our results indicate that the release of multiple anti-inflammatory and pro-angiogenic mediators by M2 macrophages could account for the decreased therapy efficacy for those patients that were treated with the combination of cetuximab, the anti-VEGF MAb bevacizumab and chemotherapy (6) . The finding that M2 macrophages encoding the high affinity FcgRIIIA (valine-carriers) displayed a more pronounced activation (figure 4) corroborated our previous Activation of M2 macrophages by cetuximab 7 observation that patients with this high affinity receptor had an even worse progression-free survival than those with 158-Phe homozygosity (7) . Strikingly, removal of the high-affinity valine-carriers from the CAIRO2 cohort revealed that the addition of cetuximab did not lead to worse clinical outcome, compared with the trial arm of conventional therapy. On the contrary, the homozygous 158-Phe FcgRIIIA patients seemed to benefit from the addition of cetuximab. However, this analysis was performed on the KRAS wild type patients and groups sizes were too small to draw firm conclusions. Notably, bevacizumab binds soluble VEGF and therefore does not cross-link FcgRs and activate intratumoral macrophages (figure 2).
One intriguing question still remains: why does cetuximab mediate anti-tumor effects as a single agent (18, 19) , whereas its addition to bevacizumab plus chemo-therapy leads to worse survival? Based on our findings, we speculate that cetuximab induces local release of pro-tumor mediators, amongst which VEGF, and thereby neutralizes the beneficial therapeutic effect of bevacizumab. Interestingly, a clinical study with cetuximab as monotherapy for metastatic colorectal cancers also revealed an increased progression-free survival for low-affinity carriers of FcgRIIIA, especially in combination with certain FCGR2A alleles (20) . Combination with chemotherapy might tip the balance further towards macrophage activation by up-regulation of EGFR expression, as shown for fluoropyrimidines and irinotecan (21) and, importantly, also by recruiting immune-suppressive macrophages to the tumor site (22). These indirect immune effects might then overrule the direct growth-inhibiting effect of EGFR blockade.
In conclusion, therapeutic antibodies mediate a plethora of in vivo effector arms that reach beyond their on-target function or immediate complement-mediated cytotoxicity. These FcRdependent mechanisms are diverse in vivo and several factors determine the outcome and employed effector arm, including the type of tumor (solid or circulating), type of immune infiltrate (macrophages or NK cells) and combinations with other therapeutics. We now propose an adverse mechanism by which therapeutic MAbs might promote tumor growth via activation of infiltrated macrophages, which are known for their pro-angiogenic and immunesuppressive functions. Clinical testing of engineered MAbs with Fc-regions with increased affinity to FcgRs should be performed very carefully (1, 23) , because tumor-promoting effects by intratumoral M2 macrophages could lead to tumor promotion instead of tumor repression. 
